Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 16/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188689 | 0.88 | CDC7 (0.46) | CDC7PIM1PIM2MAPKAPK2PARP1 | |
| SCHEMBL4991466 | 0.88 | CDC7 (0.46) | CDC7PIM1PIM2MAPKAPK2LRRK2 | |
| SCHEMBL14188488 | 0.87 | CDC7 (0.51) | CDC7PIM1PIM2MAPKAPK2LRRK2 | |
| SCHEMBL14188404 | 0.86 | CDC7 (0.46) | CDC7PIM1PIM2PARP1CCNA2 | |
| SCHEMBL4993638 | 0.86 | CDC7 (0.48) | CDC7PIM1PIM2LRRK2PARP1 | |
| SCHEMBL5002510 | 0.86 | CDC7 (0.48) | CDC7PIM1PIM2MAPKAPK2LRRK2 | |
| SCHEMBL4999856 | 0.86 | CDC7 (0.51) | CDC7PIM1PIM2MAPKAPK2LRRK2 | |
| SCHEMBL14188474 | 0.84 | CDC7 (0.46) | CDC7PIM1PIM2PARP1 | |
| SCHEMBL14188525 | 0.84 | CDC7 (0.46) | CDC7PIM1PIM2CCNA2CDK2 | |
| SCHEMBL14188576 | 0.83 | CDC7 (0.47) | CDC7PIM1PIM2MAPKAPK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885PIM1 539/4885PIM2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.